| A current update on human papillomavirus-associated head and neck cancers E Tumban Viruses 11 (10), 922, 2019 | 235 | 2019 |
| Gardasil-9: A global survey of projected efficacy L Zhai, E Tumban Antiviral research 130, 101-109, 2016 | 192 | 2016 |
| A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2 E Tumban, J Peabody, DS Peabody, B Chackerian PloS one 6 (8), e23310, 2011 | 146 | 2011 |
| VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus E Tumban, J Peabody, M Tyler, DS Peabody, B Chackerian PloS one 7 (11), e49751, 2012 | 112 | 2012 |
| Lead SARS-CoV-2 candidate vaccines: expectations from phase III trials and recommendations post-vaccine approval E Tumban Viruses 13 (1), 54, 2020 | 101 | 2020 |
| A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants E Tumban, J Peabody, DS Peabody, B Chackerian Vaccine 31 (41), 4647-4654, 2013 | 85 | 2013 |
| Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2 E Tumban, P Muttil, CAA Escobar, J Peabody, D Wafula, DS Peabody, ... Vaccine 33 (29), 3346-3353, 2015 | 75 | 2015 |
| Optimized formulation of a thermostable spray-dried virus-like particle vaccine against human papillomavirus S Saboo, E Tumban, J Peabody, D Wafula, DS Peabody, B Chackerian, ... Molecular pharmaceutics 13 (5), 1646-1655, 2016 | 72 | 2016 |
| Secondary structure of dengue virus type 4 3′ untranslated region: impact of deletion and substitution mutations TA Romero, E Tumban, J Jun, WB Lott, KA Hanley Journal of general virology 87 (11), 3291-3296, 2006 | 63 | 2006 |
| Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer L Zhai, R Yadav, NK Kunda, D Anderson, E Bruckner, EK Miller, R Basu, ... Antiviral research 166, 56-65, 2019 | 58 | 2019 |
| A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9 L Zhai, J Peabody, YYS Pang, J Schiller, B Chackerian, E Tumban Antiviral research 147, 116-123, 2017 | 56 | 2017 |
| Zika virus on a spreading spree: what we now know that was unknown in the 1950’s R Basu, E Tumban Virology journal 13, 1-9, 2016 | 56 | 2016 |
| Virus-like particle-based L2 vaccines against HPVs: where are we today? R Yadav, L Zhai, E Tumban Viruses 12 (1), 18, 2019 | 55 | 2019 |
| The use of hybrid virus‐like particles to enhance the immunogenicity of a broadly protective HPV vaccine M Tyler, E Tumban, DS Peabody, B Chackerian Biotechnology and bioengineering 111 (12), 2398-2406, 2014 | 54 | 2014 |
| Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells R Basu, L Zhai, A Contreras, E Tumban Vaccine 36 (10), 1256-1264, 2018 | 46 | 2018 |
| Second-generation prophylactic HPV vaccines: successes and challenges M Tyler, E Tumban, B Chackerian Expert review of vaccines 13 (2), 247-255, 2014 | 46 | 2014 |
| Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing M Tyler, E Tumban, A Dziduszko, MA Ozbun, DS Peabody, B Chackerian Vaccine 32 (34), 4267-4274, 2014 | 41 | 2014 |
| Virus-like particle vaccines and platforms for vaccine development M Kheirvari, H Liu, E Tumban Viruses 15 (5), 1109, 2023 | 33 | 2023 |
| Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature J Peabody, P Muttil, B Chackerian, E Tumban Papillomavirus Research 3, 116-120, 2017 | 30 | 2017 |
| Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9 NK Kunda, J Peabody, L Zhai, DN Price, B Chackerian, E Tumban, ... Human Vaccines & Immunotherapeutics, 2019 | 25 | 2019 |
